Saturday 17 October 2026
Export UPB’s income statement to Excel — free account
Upstream Bio, Inc.
Upstream Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue fell 17.5%, EPS grew 1.35% and free cash flow grew 9.33%, each against the same quarter a year earlier.
2.76
0.61
−18.10%
Follow UPB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 2.56 |
+8 more quarters Free account |
P/S ratio |
119.57 | 147.20 | 512.30 | 362.43 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.60) | (10.22) | (47.73) | (45.61) | |
P/B ratio |
1.39 | 1.61 | 4.30 | 2.68 | |
Price to Tangible BV |
1.39 | 1.61 | 4.30 | 2.68 | |
EV/Sales |
36.83 | 58.52 | 392.64 | 229.37 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.85) | (1.39) | (8.41) | (5.25) | |
EV/FCF |
(0.85) | (1.39) | (8.39) | (5.22) | |
Quick Ratio |
26.24 | 21.63 | 25.44 | 31.33 | |
Current Ratio |
27.99 | 23.14 | 26.15 | 32.67 | |
Net Debt/EBITDA |
6.17 | 6.65 | 7.63 | 9.82 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.90 | 1.18 | 0.72 | 0.66 | |
Capex/Depreciation |
0.00 | 0.00 | (0.04) | 0.59 | |
Research and Development Expense of Revenue |
4,668.69% | 3,536.27% | 6,013.32% | 4,827.96% | |
Selling, General and Administrative Expense of Revenue |
912.29% | 781.82% | 997.90% | 811.42% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
563.26% | 449.42% | 375.15% | 379.80% | |
Graham Net Nets |
0.71 | 0.62 | 0.23 | 0.37 | |
Graham Number |
0.00 | 0.00 | 0.00 | 34.03 | |
Earnings Yield |
(41.91%) | (32.33%) | (9.83%) | 38.99% | |
Free Cash Flow Yield |
(36.20%) | (28.69%) | (9.14%) | (12.11%) | |
Revenue per Share |
0.01 | 0.02 | 0.01 | 0.01 | |
Operating CF per Share |
(0.65) | (0.88) | (0.57) | (0.41) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.65) | (0.88) | (0.57) | (0.41) | |
Cash per Share |
4.79 | 5.42 | 6.34 | 6.91 | |
Shareholders Equity per Share |
4.97 | 5.60 | 6.31 | 7.02 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.97 | 5.60 | 6.31 | 7.02 | |
Free Cash Flow |
(35.62) | (47.85) | (30.68) | (22.30) | |
Working Capital |
269.61 | 302.61 | 338.35 | 377.11 | |
Capital Expenditures |
— | — | (0.05) | (0.06) | |
Net Current Asset Value |
269.39 | 302.22 | 337.80 | 376.41 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.08 | 0.09 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.85 | 0.80 | 0.64 | 0.65 | |
Average Payables |
2.43 | 3.21 | 3.38 | 4.43 | |
Average Assets |
350.85 | 387.11 | 417.75 | 311.95 | |
Average Common Equity |
339.85 | 374.80 | 404.81 | 109.14 |
Columns are period end dates